Last updated: Sep 9, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT07300475 | 1 | Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients | PD-1 + chemotherapy agents -- immune checkpoint inhibitor + chemotherapy |
| NCT07287917 | 1, 2 | Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors | Polyamine transport inhibitor (AMXT 1501) + ornithine decarboxylase inhibitor (DFMO) + estrogen receptor antagonist (fulvestrant) + AKT inhibitor (capivasertib) + PD-1 -- immune checkpoint inhibitor (pembrolizumab) |
| NCT06430541 | 1 | Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence | 5-HT2A receptor agonist -- psychedelic agent (psychedelic drug) |
| NCT06377852 | 3 | The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study | CDK4/6 -- cyclin-dependent kinase 4/6 inhibitors |
| NCT05827081 | 3 | Phase IIIb Study of Ribociclib + ET in Early Breast Cancer | CDK4/6 -- cyclin-dependent kinase 4/6 inhibitor |
| Sponsor | Recruiting trials |
|---|---|
| Fudan University | 107 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 40 |
| Memorial Sloan Kettering Cancer Center | 36 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 29 |
| The First Affiliated Hospital with Nanjing Medical University | 27 |
Countries/regions with the most active trial sites for breast cancer. A multi-site trial is counted once per country/region.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| Jun 1, 2027 | NCT04430595 | Multi-4SCAR-T Therapy Targeting Breast Cancer | Her2 + GD2 + CD44v6 -- chimeric antigen receptor T cells (CAR-T) |
| Jun 2027 | NCT04861077 | Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI) | Tumor hypoxia -- 18F-fluoromisonidazole PET with MRI (diagnostic imaging) |
| Dec 2026 | NCT07785856 | Study of Trastuzumab Deruxtecan (T-DXd) in Combination With a RAGE Inhibitor in Patients With T-DXd-Resistant HER2-Positive or HER2-Low Metastatic Breast Cancer | HER2 + RAGE -- antibody-drug conjugate (T-DXd) combined with RAGE inhibitor |
| Nov 2026 | NCT07730125 | Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies | Regulatory T cells -- gene-edited cell therapy |
| Oct 30, 2026 | NCT07272642 | A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors. | LRRC15 -- radiolabeled monoclonal antibody (radioimmunotherapy) |
| Oct 1, 2026 | NCT07300475 | Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients | PD-1 + chemotherapy agents -- immune checkpoint inhibitor + chemotherapy |
| Oct 1, 2026 | NCT07553390 | Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers | TGFBR2 -- knockout; TROP2 -- chimeric antigen receptor (CAR) NK cells; HER2 -- antibody-drug conjugate (trastuzumab deruxtecan) |
| Oct 2026 | NCT07581314 | Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC) | Telomerase -- inhibitor (Zn-Telomir) |
You've seen the breast cancer landscape. Now find the trials that fit your case.
Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.
Find My Matches →Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.